| Enrolling By Invitation | An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE) Bipolar Depression, Bipolar I Disorder, Bipolar Disorder | Phase 3 | 2025-10-30 |
| Recruiting | A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disord Bipolar Disorder, Bipolar Depression, Bipolar I Disorder | Phase 3 | 2025-08-08 |
| Recruiting | A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) Major Depressive Disorder | Phase 3 | 2025-07-08 |
| Enrolling By Invitation | An Open-Label Study of Azetukalner in Major Depressive Disorder Major Depressive Disorder | Phase 3 | 2025-03-18 |
| Recruiting | A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder Major Depressive Disorder | Phase 3 | 2024-12-20 |
| Recruiting | A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) Focal Onset Seizures | Phase 3 | 2023-05-09 |
| Enrolling By Invitation | An Open-label Study of XEN1101 in Epilepsy Focal Epilepsy, Tonic-Clonic Seizures | Phase 3 | 2023-04-25 |
| Recruiting | A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures Primary Generalized Tonic-Clonic Seizures | Phase 3 | 2023-02-14 |
| Completed | A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures Focal Onset Seizures | Phase 3 | 2022-11-18 |
| Completed | A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder Major Depressive Disorder | Phase 2 | 2022-05-19 |
| Terminated | An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE Epilepsy, Epilepsy in Children, Epilepsy; Seizure | Phase 3 | 2021-08-17 |
| Completed | Single-dose Mass Balance Recovery and Metabolite Profile and Identification of 14C-XEN1101 Healthy Volunteers | Phase 1 | 2021-07-14 |
| Terminated | XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy Epilepsy, Epilepsy in Children, Epilepsy; Seizure | Phase 3 | 2021-03-29 |
| Active Not Recruiting | A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy Focal Epilepsy | Phase 2 | 2019-01-30 |
| Completed | Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XEN901 Healthy Volunteers | Phase 1 | 2018-02-19 |
| Completed | Safety, Tolerability, Pharmacokinetics and Effects on Transcranial Magnetic Stimulation of Oral Doses of XEN11 Healthy Male Volunteers | Phase 1 | 2018-02-13 |
| Completed | Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of XEN1101. Healthy Volunteers | Phase 1 | 2017-11-13 |
| Completed | A Safety, Tolerability, Efficacy and Exposure Study of XEN801 Topical Gel Acne Vulgaris | Phase 1 / Phase 2 | 2015-09-17 |
| Completed | Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Primary Erythromelalgia, Inherited Erythromelalgia | Phase 1 / Phase 2 | 2011-12-01 |
| Completed | A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic N Postherpetic Neuralgia | Phase 2 | 2010-08-01 |
| Completed | Study of XPF-001 in the Treatment of Pain From Primary/Inherited Erythromelalgia (IEM) Primary Erythromelalgia, Inherited Erythromelalgia | Phase 1 / Phase 2 | 2010-04-01 |
| Completed | Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction Dental Pain | Phase 2 | 2009-09-01 |
| Completed | Single and Multiple Ascending Dose Safety Study of XPF-001 in Healthy Volunteers Healthy Human Volunteers | Phase 1 | 2008-11-01 |